ANAVEX LIFE SCIENCES CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.39 USD | -0.59% |
|
-10.79% | -63.59% |
Presenter SpeechUnknown Analyst (Analysts)Good morning, everyone, and thanks again for attendi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimerâs disease, Parkinsonâs disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Companyâs product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
Calendar
2024-05-08
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.39
USD
Average target price
40
USD
Spread / Average Target
+1,079.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.59% | 278M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.52% | 22.02B | |
| -17.84% | 20.9B | |
| -8.86% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- AVXL Stock
- News Anavex Life Sciences Corp.
- Transcript : Anavex Life Sciences Corp. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 08
